- Home
- CIGI vs IONS Comparison
CIGI vs IONS Comparison
Compare CIGI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGI
- IONS
- Stock Information
- Founded
- CIGI 1972
- IONS 1989
- Country
- CIGI Canada
- IONS United States
- Employees
- CIGI N/A
- IONS N/A
- Industry
- CIGI
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CIGI
- IONS Health Care
- Exchange
- CIGI Nasdaq
- IONS Nasdaq
- Market Cap
- CIGI 6.9B
- IONS 6.0B
- IPO Year
- CIGI N/A
- IONS 1991
- Fundamental
- Price
- CIGI $140.36
- IONS $32.68
- Analyst Decision
- CIGI Buy
- IONS Buy
- Analyst Count
- CIGI 6
- IONS 18
- Target Price
- CIGI $163.08
- IONS $62.00
- AVG Volume (30 Days)
- CIGI 92.4K
- IONS 1.5M
- Earning Date
- CIGI 02-06-2025
- IONS 02-19-2025
- Dividend Yield
- CIGI 0.21%
- IONS N/A
- EPS Growth
- CIGI 586.57
- IONS N/A
- EPS
- CIGI 3.10
- IONS N/A
- Revenue
- CIGI $4,555,575,000.00
- IONS $803,067,000.00
- Revenue This Year
- CIGI $11.65
- IONS N/A
- Revenue Next Year
- CIGI $11.80
- IONS $10.85
- P/E Ratio
- CIGI $45.33
- IONS N/A
- Revenue Growth
- CIGI 5.40
- IONS 30.57
- 52 Week Low
- CIGI $101.01
- IONS $31.40
- 52 Week High
- CIGI $156.96
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- CIGI 54.47
- IONS 40.58
- Support Level
- CIGI $126.65
- IONS $31.40
- Resistance Level
- CIGI $138.78
- IONS $35.37
- Average True Range (ATR)
- CIGI 2.96
- IONS 1.31
- MACD
- CIGI 1.06
- IONS -0.23
- Stochastic Oscillator
- CIGI 93.68
- IONS 29.09
About CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc is a real estate services and investment management company. The company provides commercial real estate professional services and investment management to corporate and institutional clients around the world. It's primary service lines are Outsourcing & Advisory, Investment Management, Leasing and Capital Markets. Operationally, company is organized into four distinct segments: Americas; Europe, Middle East and Africa, Asia and Australasia and Investment Management.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.